Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor

Sumana Devata, Edward Kim

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Pancreatic neuroendocrine tumors (PNETs) are relatively rare tumors that arise in the endocrine cells of the pancreas. Historically, somatostatin analogues have been used in this disease primarily for symptom control and, to a limited extent, disease stability. More recently, sunitinib and everolimus have been approved for advanced stage PNETs based on a survival benefit. However, both agents have a <10% actual response rate and cause nontrivial side effect profiles that limit duration of therapy. In locally advanced disease, there is a paucity of data to support an optimal neoadjuvant approach with the expectation of down-staging to allow for curative resection. We describe in this case a young woman who was successfully down-staged using a chemotherapy regimen of capecitabine and temozolomide with minimal toxicity.

Original languageEnglish (US)
Pages (from-to)622-626
Number of pages5
JournalCase Reports in Oncology
Volume5
Issue number3
DOIs
StatePublished - Sep 2012
Externally publishedYes

Keywords

  • Capecitabine
  • Pancreatic neuroendocrine tumor
  • Temozolomide

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor'. Together they form a unique fingerprint.

Cite this